|
|
View Clinical Trial (Medical Research Study)
|
A Study of Pemetrexed, Carboplatin and Bevacizumab in Patients With Nonsquamous Non-Small Cell Lung Cancer - NCT00762034-60031 (Clinical Trial 243779)
Permalink: http://www.ClinicalConnection.com/exp/ExpandedPatientViewStudy243779.aspx
|
** Please review additional "Nearby Studies" on right ----->
|
|
 |
 |
|
| City: |
|
Gurnee |
|
State:
|
|
IL |
| Zip Code: |
|
60031 |
| Conditions: |
|
Non-small Cell Lung Cancer |
| Purpose: |
|
This study will compare overall survival in patients with Stage IIIB or IV nonsquamous
non-small cell lung cancer.
|
| Study summary: |
|
|
| Criteria: |
|
Inclusion Criteria:
- You must sign an informed consent document for clinical research.
- You must have Stage IIIB or Stage IV nonsquamous non-small cell lung cancer.
- You must not have received any prior treatment for your disease.
- Prior radiation therapy is allowed to < 25% of the bone marrow; however, prior
radiation to the whole pelvis is not allowed. If you have had radiation therapy to
the chest, you are not eligible to participate.
- You must be at least 18 years of age or older.
- You must have measureable tumor lesions according to the Response Evaluation Criteria
in Solid Tumors (RECIST) or disease can be evaluated on CT scan.
- Your test results assessing the function of blood forming tissue, kidneys and liver
must be satisfactory.
- Women must be sterile, postmenopausal or on contraception and men must be sterile
(e.g. post-vasectomy) or on contraception.
Exclusion Criteria:
- You cannot have clinically significant third-space fluid collections (e.g. ascites
or pleural effusions that cannot be controlled by drainage or other procedures).
- You cannot have NSCLC of predominantly squamous cell histology.
- You cannot have known central nervous system (CNS) disease, other than stable,
treated brain metastasis.
- You cannot have undergone a surgical procedure, open biopsy, open pleurodesis, or
significant traumatic injury within 28 days of starting the study treatment, or have
an anticipated need for major surgery during the study.
- You cannot have a history of gastrointestinal fistula, perforation, or abscess,
inflammatory bowel disease, or diverticulitis.
- You are currently receiving ongoing treatment with full-dose warfarin or equivalent.
- You cannot have significant vascular disease, serious cardiac conditions (such as
heart attack), stroke or transient ischemic attack within 6 months of the trial.
- You cannot have evidence of bleeding diathesis or coagulopathy (in the absence of
therapeutic anticoagulation).
- You cannot have inadequately controlled hypertension, or a history of hypertensive
crisis or hypertensive encephalopathy.
- You cannot have a serious, nonhealing wound, active ulcer, or untreated bone
fracture.
- You cannot have another form of cancer, other than superficial basal cell and
superficial squamous (skin) cell, or carcinoma in situ of the cervix within the
last 5 years.
- You cannot have received an investigational treatment within 30 days prior to the
trial.
- You cannot have previously received treatment with paclitaxel, carboplatin,
pemetrexed, or bevacizumab.
- You cannot be pregnant or breast-feeding.
- You cannot have a known sensitivity to any component of paclitaxel, carboplatin,
pemetrexed, or bevacizumab.
- You cannot have a history of hemoptysis (coughing blood) within 3 months prior to the
trial.
- You are unable to stop taking aspirin more than 1.3 grams per day or other
nonsteroidal anti-inflammatory drugs (NSAIDs).
- You are unable or unwilling to take folic acid or vitamin B12 supplementation.
- You are unable to take corticosteroids.
- You have any other on-going illnesses including active infections that may not allow
you to adhere to the requirements of the trial. |
|
|
|
| Study is available at: |
|
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Gurnee, IL 60031
United States
Primary Contact:
There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559)
Phone: 1-317-615-4559 |
|
|
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
|
| Trials Alerts: |
|
If you would like to be
notified of new clinical trials as they become available please
register for a free account.
|
|
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
March 16, 2010 |
Modifications to
this listing: |
|
Only selected fields are shown, please use the link
above to view all information about this clinical trial. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Clinical trials are medical research studies designed to test the safety and/or
effectiveness of new drugs, devices, or treatments in humans. These studies are
conducted worldwide for a range of conditions and illnesses. Learn more about
clinical research and participating in a study at
About Clinical Trials.
|
|
|
|
|
|
|
|